281 related articles for article (PubMed ID: 22457289)
1. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
5. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.
Bergmann-Leitner ES; Duncan EH; Leitner WW; Neutzner A; Savranskaya T; Angov E; Tsokos GC
Vaccine; 2007 Nov; 25(45):7732-6. PubMed ID: 17931754
[TBL] [Abstract][Full Text] [Related]
6. Importance of the Immunodominant CD8
Gibbins MP; Müller K; Glover M; Liu J; Putrianti ED; Bauza K; Reyes-Sandoval A; Matuschewski K; Silvie O; Hafalla JCR
Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32719159
[TBL] [Abstract][Full Text] [Related]
7. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
Tartz S; Rüssmann H; Kamanova J; Sebo P; Sturm A; Heussler V; Fleischer B; Jacobs T
Vaccine; 2008 Nov; 26(47):5935-43. PubMed ID: 18804138
[TBL] [Abstract][Full Text] [Related]
8. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates.
Annoura T; Ploemen IH; van Schaijk BC; Sajid M; Vos MW; van Gemert GJ; Chevalley-Maurel S; Franke-Fayard BM; Hermsen CC; Gego A; Franetich JF; Mazier D; Hoffman SL; Janse CJ; Sauerwein RW; Khan SM
Vaccine; 2012 Mar; 30(16):2662-70. PubMed ID: 22342550
[TBL] [Abstract][Full Text] [Related]
9. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
10. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
[TBL] [Abstract][Full Text] [Related]
11. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
[TBL] [Abstract][Full Text] [Related]
12. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites.
Leitner WW; Seguin MC; Ballou WR; Seitz JP; Schultz AM; Sheehy MJ; Lyon JA
J Immunol; 1997 Dec; 159(12):6112-9. PubMed ID: 9550412
[TBL] [Abstract][Full Text] [Related]
13. Defining rules of CD8(+) T cell expansion against pre-erythrocytic Plasmodium antigens in sporozoite-immunized mice.
Billman ZP; Kas A; Stone BC; Murphy SC
Malar J; 2016 Apr; 15():238. PubMed ID: 27113469
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
15. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E
Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.
Almeida AP; Dias MO; Vieira Cde A; Chávez-Olórtegui C; Gazzineli RT; Rodrigues MM; Fujiwara RT; Bruna-Romero O
Vaccine; 2014 Apr; 32(19):2181-7. PubMed ID: 24582631
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
[TBL] [Abstract][Full Text] [Related]
20. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
